Italians Share Novel Operating Room Research Using UVDI-360 Room Sanitizer

UltraViolet Devices Inc. (UVDI) has announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at this month’s Society for Healthcare Epidemiology of America (SHEA) Spring Conference.

The Joint Commission issues Sentinel Event Alert on optimizing medication safety with smart infusion pumps

A new Sentinel Event Alert from The Joint Commission, “Optimizing smart infusion pump safety with DERS,” describes how built-in dose error reduction software (DERS) can improve patient safety.

Hensler Bone Press Receives CE Certification

Hensler Surgical Technologies has announced its newly obtained CE mark for the Hensler Bone Press (HBP).

Healthmark Offers New Anti-Fatigue Mat

Healthmark Industries has introduced an Anti-Fatigue Mat to its Personal Protection Equipment (PPE) product line.

CareAdvantage Helps Health Systems Address HAI Risks


The Johnson & Johnson Medical Devices Companies (JJMDC)* have announced they are working with the Medical University of South Carolina (MUSC) in its commitment to drive toward zero, by identifying opportunities to reduce the risk of infection for patients receiving care within its OR and ambulatory surgery facilities and sharing evidence-based learnings and insights. JJMDC will assess specific risks and work closely with MUSC to implement evidence-based infection prevention strategies, related to appropriate use of JJMDC surgical products.

The need to address infection risk is an increasing priority for health systems, as evidenced by the recently revised Centers for Disease Control and Prevention Guidelines for the Prevention of Surgical Site Infections (SSIs), 2017. This convergence is driving demand to optimize care and reduce variation in patient outcomes, especially when patient outcomes are adversely affected by healthcare-associated infections (HAIs). These infections can create significant financial challenges for providers. On a per-case basis, central line-associated bloodstream infections (CLABSIs) and SSIs are among the costliest healthcare-associated infections: SSIs and CLABSIs account for more than half of the total annual costs associated with the most common HAIs. Overall, HAIs cost hospitals billions of dollars annually. HAIs are also one of the leading causes of death in U.S. acute care hospitals, with nearly 90,000 patients estimated to die annually and approximately two million patients affected by HAIs each year.

“Healthcare-associated infections are a very real concern that can have significant ramifications for everyone involved. We are committed to being a leader in infection risk reduction efforts and have engaged the Johnson & Johnson Medical Devices Companies to help us reduce infection risk in our surgical facilities,” said Danielle Scheurer, MD, MSCR, SFHM, Hospitalist and Chief Quality Officer, Associate Professor of Medicine, Medical University of South Carolina. “Through its evidence-based approach, JJMDC is helping us to identify and address our needs specific to infection risk management, including appropriate techniques for its products, and provide training and education resources for our care team members. Our common goal is providing the highest level of patient care possible.”

The engagement with MUSC leverages the unique capabilities of CareAdvantage from the Johnson & Johnson Medical Devices Companies**, specifically its Infection Risk Management capability designed to provide a holistic, data-driven approach to help hospitals and health systems address the risks of infection throughout the care pathway.

The Infection Risk Management capability helps address risk factors of costly infections, can reduce variation in clinical practices and purchasing patterns, and enables engagement of patients and staff throughout an episode of care, potentially helping hospitals and health systems adjust to the market shift from volume to value-based care. The program starts with listening and provides evidence-based practices that can be used to address risk factors for bloodstream infections (BSIs) and SSIs using the JJMDC portfolio, including patient resources, to facilitate optimal wound healing post-surgery.

“Infection risk management has never been more important to helping hospitals meet the Triple Aim goal of reducing cost, improving outcomes and increasing patient satisfaction. Healthcare-associated infections can create significant financial and operational challenges for provider organizations. Based on careful evaluation of evidence, our approach focuses on effective, efficient patient care delivery and fits naturally as a priority in successful value-based care practices,” said Christina Farup, M.D., Vice President, Health Economics and Market Access, Johnson & Johnson Medical Devices Companies.

For more information about CareAdvantage from the Johnson & Johnson Medical Devices Companies, including the Infection Risk Management capability, visit For discussions on a variety of topics in value-based care, visit Voices for Value on LinkedIn.


* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.


**CareAdvantage from the Johnson & Johnson Medical Devices Companies is offered through Johnson & Johnson Health Care Systems Inc.





Submit a Comment

Your email address will not be published. Required fields are marked *